Docstoc

MRSA Partnering 2007-2012

Document Sample
MRSA Partnering 2007-2012 Powered By Docstoc
					MRSA Partnering 2007-2012
Published : July 2012                No. of Pages : 100                    Price:US$995




The MRSA Partnering 2007-2012 report provides understanding and access to the MRSA partnering
deals and agreements entered into by the worlds leading healthcare companies.

Top MRSA deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The MRSA Partnering 2007-2012 provides understanding and access to the MRSA partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of MRSA partnering deals. The majority of deals are discovery or
development stage whereby the licensee obtains a right or an option right to license the licensors MRSA
technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into
the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual MRSA deals and contract
documents as submitted to the Securities Exchange Commission by companies and their partners, where
available. Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.

Report scope

MRSA Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access
to MRSA trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:
Trends in MRSA dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading MRSA deals by value since 2007
In MRSA Partnering 2007-2012, the available deals are listed by:
Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.

MRSA Partnering 2007-2012 provides the reader with the following key benefits:
In-depth understanding of MRSA deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 50 actual MRSA deals entered into by the world’s biopharma companies
since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

MRSA Partnering 2007-2012

Table Of contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in MRSA partnering
2.1. Introduction
2.2. MRSA partnering over the years
2.3. Bigpharma MRSA dealmaking activity
2.4. MRSA partnering by deal type
2.5. MRSA partnering industry sector
2.6. MRSA partnering by stage of development
2.7. MRSA partnering by technology type
2.8. Disclosed financial deal terms for MRSA partnering
2.8.1 MRSA headline values
2.8.2 MRSA upfront payments
2.8.3 MRSA milestone payments
2.8.4 MRSA royalty rates

Chapter 3 – Leading MRSA deals
3.1. Introduction
3.2. Top MRSA deals by value
3.3. Top MRSA deals involving bigpharma

Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Figures

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:2
posted:7/17/2012
language:English
pages:4
Description: The MRSA Partnering 2007-2012 report provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies.